<DOC>
	<DOC>NCT01005069</DOC>
	<brief_summary>The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with type-II-diabetes mellitus.</brief_summary>
	<brief_title>Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Fasting capillary blood glucose of 127249 mg/dL at screening BMI &gt;= 18.5 kg/m^2 or waist circumference of &gt;= 90 cm (male) or &gt;= 80 cm (female) Normal liver function Normal renal function OHAnaive typeIIdiabetic patients Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia Uncontrolled hypertension History of or current treatment with insulin Current treatment with systemic corticosteroids or herbal (alternative) medicines History of renal and/or liver disease Pregnant or breast feeding females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>DLBS-32</keyword>
	<keyword>fasting plasma glucose</keyword>
	<keyword>insulin resistance</keyword>
</DOC>